16358366

Source:http://linkedlifedata.com/resource/pubmed/id/16358366

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0003873, umls-concept:C0018026, umls-concept:C0020336, umls-concept:C0036078, umls-concept:C0087111, umls-concept:C0205195, umls-concept:C0717758
pubmed:issue	2
pubmed:dateCreated	2006-2-8
pubmed:abstractText	To prospectively determine the efficacy and safety of etanercept in combination with sulfasalazine (SSZ), hydroxychloroquine (HCQ), and gold in the treatment of rheumatoid arthritis (RA).
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/7501984
pubmed:citationSubset	IM
pubmed:chemical	http://linkedlifedata.com/resource/pubmed/chemical/Antirheumatic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Gold, http://linkedlifedata.com/resource/pubmed/chemical/Hydroxychloroquine, http://linkedlifedata.com/resource/pubmed/chemical/Immunoglobulin G, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Tumor Necrosis Factor, http://linkedlifedata.com/resource/pubmed/chemical/Recombinant Fusion Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Sulfasalazine, http://linkedlifedata.com/resource/pubmed/chemical/TNFR-Fc fusion protein
pubmed:status	MEDLINE
pubmed:month	Feb
pubmed:issn	0315-162X
pubmed:author	pubmed-author:BlakelyKentK, pubmed-author:FernandezAnaA, pubmed-author:HaireClaireC, pubmed-author:LeffRobertR, pubmed-author:O'DellJames RJR, pubmed-author:PalmerWilliamW, pubmed-author:PetersenKaraK, pubmed-author:SchnedEricE
pubmed:issnType	Print
pubmed:volume	33
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	213-8
pubmed:meshHeading	pubmed-meshheading:16358366-Adult, pubmed-meshheading:16358366-Aged, pubmed-meshheading:16358366-Antirheumatic Agents, pubmed-meshheading:16358366-Arthritis, Rheumatoid, pubmed-meshheading:16358366-Drug Therapy, Combination, pubmed-meshheading:16358366-Female, pubmed-meshheading:16358366-Gold, pubmed-meshheading:16358366-Health Status, pubmed-meshheading:16358366-Humans, pubmed-meshheading:16358366-Hydroxychloroquine, pubmed-meshheading:16358366-Immunoglobulin G, pubmed-meshheading:16358366-Injections, Intramuscular, pubmed-meshheading:16358366-Injections, Subcutaneous, pubmed-meshheading:16358366-Male, pubmed-meshheading:16358366-Middle Aged, pubmed-meshheading:16358366-Prospective Studies, pubmed-meshheading:16358366-Receptors, Tumor Necrosis Factor, pubmed-meshheading:16358366-Recombinant Fusion Proteins, pubmed-meshheading:16358366-Severity of Illness Index, pubmed-meshheading:16358366-Sulfasalazine, pubmed-meshheading:16358366-Treatment Outcome
pubmed:year	2006
pubmed:articleTitle	Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis.
pubmed:affiliation	Department of Internal Medicine, University of Nebraska Medical Center, Omaha, 983025, USA. jrodell@unmc.edu
pubmed:publicationType	Journal Article, Clinical Trial, Multicenter Study